Outlook Therapeutics (OTLK) Stock Statistics & Valuation Metrics

Outlook Therapeutics has a market cap or net worth of $37.83M. The enterprise value is $84.93M.

Outlook Therapeutics has 64,114,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Outlook Therapeutics’s return on equity (ROE) is 1.94 and return on invested capital (ROIC) is 240.82%.

The current PE Ratio of Outlook Therapeutics is ―. Outlook Therapeutics’s PEG ratio is <0.00001.

In the last 12 months, Outlook Therapeutics had revenue of 1.41T and earned -62.42T in profits. Earnings per share was -1.79.

In the last 12 months, operating cash flow was -56.43M and capital expenditures 0.00, giving a free cash flow of -56.43M billion.

Outlook Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Outlook Therapeutics upcoming earnings date is Feb 13, 2026, TBA (Confirmed).

Outlook Therapeutics as a current ratio of 0.38, with Debt / Equity ratio of -0.77%

In the past 12 months, Outlook Therapeutics has paid -1.55T in taxes.

Outlook Therapeutics EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.15.

Outlook Therapeutics has $8.90M in cash and marketable securities with $34.70M in debt, giving a net cash position of -$25.80M billion.

Gross margin is 65.22%, with operating margin of -4744.25%, and net profit margin of -4416.22%.

The average price target for Outlook Therapeutics is $3.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy